RBC Capital Maintains Outperform on Alpine Immune Sciences, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an Outperform rating on Alpine Immune Sciences (NASDAQ:ALPN) and raises the price target from $19 to $22.
November 03, 2023 | 6:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating on Alpine Immune Sciences and raises the price target from $19 to $22. This could potentially lead to a positive impact on the company's stock price.
The raised price target by RBC Capital indicates a positive outlook for Alpine Immune Sciences. This could potentially lead to an increase in the company's stock price as it shows the analyst's confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100